Asahi Kasei Pharma Strengthens Global Reach with Exclusive License Agreement for anti-CX3CR1 Antibody
Asahi Kasei Pharma has secured an exclusive license agreement with Chiome Bioscience for their humanized anti-CX3CR1 antibody, currently in preclinical development. This agreement aligns with the company's Open Innovation platform and transformation into a global specialty pharmaceuticals company. The antibody targets CX3CR1, a receptor involved in immune cell migration to inflammatory sites.
The partnership follows Asahi Kasei's recent acquisition of Calliditas Therapeutics, known for TARPEYO™, a therapy for IgA nephropathy. Through their 'One AK Pharma' initiative, which unifies operations in Japan and the U.S., the company aims to achieve $3 billion in annual pharmaceutical sales by 2030, focusing on immunology, transplantation, and related diseases.
Asahi Kasei Pharma ha stipulato un accordo di licenza esclusivo con Chiome Bioscience per il loro anticorpo anti-CX3CR1 umanizzato, attualmente in fase di sviluppo preclinico. Questo accordo si allinea con la piattaforma di Open Innovation dell'azienda e la sua trasformazione in una società globale di farmaci specializzati. L'anticorpo mira a CX3CR1, un recettore coinvolto nella migrazione delle cellule immunitarie verso i siti infiammatori.
Il partenariato segue l'acquisizione recente da parte di Asahi Kasei di Calliditas Therapeutics, nota per TARPEYO™, una terapia per la nefropatia da IgA. Attraverso la loro iniziativa 'One AK Pharma', che unifica le operazioni in Giappone e negli Stati Uniti, l'azienda mira a raggiungere 3 miliardi di dollari di vendite farmaceutiche annuali entro il 2030, concentrandosi su immunologia, trapianti e malattie correlate.
Asahi Kasei Pharma ha asegurado un acuerdo de licencia exclusivo con Chiome Bioscience para su anticuerpo anti-CX3CR1 humanizado, que se encuentra actualmente en desarrollo preclínico. Este acuerdo se alinea con la plataforma de Innovación Abierta de la empresa y su transformación en una compañía farmacéutica especializada global. El anticuerpo tiene como objetivo CX3CR1, un receptor involucrado en la migración de células inmunitarias a sitios inflamatorios.
La asociación sigue a la reciente adquisición por parte de Asahi Kasei de Calliditas Therapeutics, conocida por TARPEYO™, una terapia para la nefropatía por IgA. A través de su iniciativa 'One AK Pharma', que unifica operaciones en Japón y EE. UU., la empresa pretende alcanzar 3 mil millones de dólares en ventas farmacéuticas anuales para 2030, centrándose en inmunología, trasplantes y enfermedades relacionadas.
아사히 카세이 제약은 현재 전임상 개발 중인 인간화된 항-CX3CR1 항체
이번 파트너십은 아사히 카세이가 최근 IgA 신병증 치료제로 알려진 TARPEYO™를 보유한 Calliditas Therapeutics를 인수한 후속 조치입니다. 일본과 미국의 운영을 통합하는 'One AK Pharma' 이니셔티브를 통해, 이 회사는 2030년까지 연간 30억 달러의 제약 매출을 달성하는 것을 목표로 하며, 면역학, 이식 및 관련 질병에 집중하고 있습니다.
Asahi Kasei Pharma a conclu un accord de licence exclusif avec Chiome Bioscience pour leur anticorps anti-CX3CR1 humanisé, actuellement en développement préclinique. Cet accord s'inscrit dans le cadre de la plateforme d'Innovation Ouverte de l'entreprise et de sa transformation en société mondiale de médicaments spécialisés. L'anticorps cible CX3CR1, un récepteur impliqué dans la migration des cellules immunitaires vers les sites inflammatoires.
Ce partenariat fait suite à l'acquisition récente par Asahi Kasei de Calliditas Therapeutics, connue pour TARPEYO™, une thérapie contre la néphropathie à IgA. Grâce à leur initiative 'One AK Pharma', qui unifie les opérations au Japon et aux États-Unis, l'entreprise vise à atteindre 3 milliards de dollars de ventes pharmaceutiques annuelles d'ici 2030, en se concentrant sur l'immunologie, la transplantation et les maladies connexes.
Asahi Kasei Pharma hat einen exklusiven Lizenzvertrag mit Chiome Bioscience für ihren humanisierten Anti-CX3CR1-Antikörper abgeschlossen, der sich derzeit in der präklinischen Entwicklung befindet. Dieser Vertrag passt zur Open-Innovation-Plattform des Unternehmens und seiner Transformation zu einem globalen Unternehmen für Spezialpharmazeutika. Der Antikörper zielt auf CX3CR1 ab, einen Rezeptor, der an der Migration von Immunzellen zu entzündlichen Stellen beteiligt ist.
Die Partnerschaft folgt auf die kürzliche Übernahme von Calliditas Therapeutics durch Asahi Kasei, die für TARPEYO™, eine Therapie gegen IgA-Nephropathie, bekannt ist. Durch ihre Initiative 'One AK Pharma', die die Aktivitäten in Japan und den USA vereint, strebt das Unternehmen an, bis 2030 einen Jahresumsatz von 3 Milliarden US-Dollar im Pharmabereich zu erreichen, mit Fokus auf Immunologie, Transplantation und verwandte Erkrankungen.
- Secured exclusive license for promising anti-CX3CR1 antibody in preclinical development
- Strategic acquisition of Calliditas Therapeutics enhances U.S. market presence
- Clear revenue target of $3 billion in annual pharmaceutical sales by 2030
- Unified global operations through 'One AK Pharma' initiative
- Anti-CX3CR1 antibody still in early preclinical stage, indicating long development timeline ahead
The anti-CX3CR1 antibody, currently in preclinical development, works by inhibiting CX3CR1, a receptor involved in immune cell migration to inflammatory sites. By accelerating its development, Asahi Kasei Pharma aims to bring an innovative therapy to market that could significantly improve patient outcomes.
“By establishing an effective co-creation framework with Chiome, we successfully brought this initiative to fruition,” said Dr. Kazunobu Konishi, Senior General Manager of Pharmaceuticals Research Center at Asahi Kasei Pharma. “We hope that this partnership will expedite the development of the anti-CX3CR1 antibody. Furthermore, we are committed to intensifying our open innovation activities to continuously secure global rights to early-stage projects, thereby enhancing our presence on the global stage.”
The licensing agreement complements the “One AK Pharma” initiative, which unifies Asahi Kasei’s pharmaceutical operations in
“We’ve integrated our pharmaceutical businesses worldwide to better achieve our mid- and long-term goals,” said Yoshikazu Aoki, President of Asahi Kasei Pharma. “This effort includes consolidating our Business Development functions in the
Through partnerships like the licensing agreement with Chiome, and a commitment to research-driven innovation, Asahi Kasei Pharma is well-positioned to address pressing global health challenges and deliver meaningful solutions that enhance quality of life.
Learn more about Asahi Kasei Pharma’s Open Innovation platform.
About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 49,000 employees worldwide, the company contributes to sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care. For more information, visit www.asahi-kasei.com.
Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211341717/en/
North America Contact:
Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com
Europe Contact:
Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu
Source: Asahi Kasei Pharma
FAQ
What is the significance of AHKSY's anti-CX3CR1 antibody license agreement?
What is AHKSY's revenue target for pharmaceutical sales by 2030?
How does the Calliditas Therapeutics acquisition benefit AHKSY?
What is AHKSY's 'One AK Pharma' initiative?
